To include your compound in the COVID-19 Resource Center, submit it here.

Biocon withdraws MAAs for trastuzumab and pegfilgrastim biosimilars

Biocon Ltd. (NSE:BIOCON; BSE:BIOCON) said it will withdraw at EMA's request MAAs for its biosimilars of trastuzumab and

Read the full 183 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE